Evolus, Inc. (EOLS)
EOLS Stock Price Chart
Explore Evolus, Inc. interactive price chart. Choose custom timeframes to analyze EOLS price movements and trends.
EOLS Company Profile
Discover essential business fundamentals and corporate details for Evolus, Inc. (EOLS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
8 Feb 2018
Employees
372.00
Website
https://www.evolus.comCEO
David Moatazedi
Description
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
EOLS Financial Timeline
Browse a chronological timeline of Evolus, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.01, while revenue estimate is $81.55m.
Earnings released on 4 May 2026
EPS came in at -$0.10 surpassing the estimated -$0.14 by +28.57%, while revenue for the quarter reached $73.14m , beating expectations by +0.85%.
Earnings released on 3 Mar 2026
EPS came in at $0.04 falling short of the estimated $0.06 by -26.30%, while revenue for the quarter reached $90.30m , beating expectations by +0.87%.
Earnings released on 5 Nov 2025
EPS came in at -$0.14 surpassing the estimated -$0.19 by +26.32%, while revenue for the quarter reached $68.97m , missing expectations by -23.04%.
Earnings released on 5 Aug 2025
EPS came in at -$0.24 falling short of the estimated -$0.09 by -166.67%, while revenue for the quarter reached $69.39m , missing expectations by -18.67%.
Earnings released on 7 May 2025
EPS came in at -$0.18 falling short of the estimated -$0.10 by -80.00%, while revenue for the quarter reached $68.07m , missing expectations by -17.31%.
Earnings released on 4 Mar 2025
EPS came in at $0.01 falling short of the estimated $0.02 by -50.00%, while revenue for the quarter reached $78.95m , beating expectations by +10.02%.
Earnings released on 6 Nov 2024
EPS came in at -$0.19 falling short of the estimated -$0.08 by -137.50%, while revenue for the quarter reached $61.09m , missing expectations by -20.65%.
Earnings released on 31 Jul 2024
EPS came in at -$0.07 falling short of the estimated -$0.06 by -23.09%, while revenue for the quarter reached $66.91m , beating expectations by +6.09%.
Earnings released on 7 May 2024
EPS came in at -$0.13 falling short of the estimated -$0.07 by -85.71%, while revenue for the quarter reached $59.33m , beating expectations by +3.51%.
Earnings released on 7 Mar 2024
EPS came in at -$0.14 falling short of the estimated -$0.07 by -100.00%, while revenue for the quarter reached $61.00m , beating expectations by +1.56%.
Earnings released on 7 Nov 2023
EPS came in at -$0.19 surpassing the estimated -$0.22 by +13.64%, while revenue for the quarter reached $49.32m , missing expectations by -13.16%.
Earnings released on 2 Aug 2023
EPS came in at -$0.22 matching the estimated -$0.22, while revenue for the quarter reached $49.35m , beating expectations by +11.11%.
Earnings released on 9 May 2023
EPS came in at -$0.17 falling short of the estimated -$0.13 by -30.77%, while revenue for the quarter reached $41.72m , beating expectations by +2.53%.
Earnings released on 8 Mar 2023
EPS came in at -$0.16 falling short of the estimated -$0.14 by -14.29%, while revenue for the quarter reached $43.65m , missing expectations by -0.33%.
Earnings released on 8 Nov 2022
EPS came in at -$0.32 falling short of the estimated -$0.27 by -18.52%, while revenue for the quarter reached $33.90m , missing expectations by -5.85%.
Earnings released on 2 Aug 2022
EPS came in at -$0.38 falling short of the estimated -$0.24 by -58.33%, while revenue for the quarter reached $37.16m , beating expectations by +1.53%.
Earnings released on 10 May 2022
EPS came in at -$0.27 surpassing the estimated -$0.41 by +34.15%, while revenue for the quarter reached $33.91m , beating expectations by +13.68%.
Earnings released on 3 Mar 2022
EPS came in at -$0.29 falling short of the estimated -$0.20 by -45.00%, while revenue for the quarter reached $34.66m , missing expectations by -0.30%.
Earnings released on 2 Nov 2021
EPS came in at -$0.26 surpassing the estimated -$0.32 by +18.75%, while revenue for the quarter reached $26.68m , beating expectations by +2.68%.
Earnings released on 4 Aug 2021
EPS came in at -$0.27 falling short of the estimated -$0.24 by -12.50%, while revenue for the quarter reached $26.10m , meeting expectations.
EOLS Stock Performance
Access detailed EOLS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
